Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Avalo Therapeutics director Jonathan Goldman exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of Avalo Therapeutics common stock at an exercise price of $0.00 per share. This reflects a derivative exercise, not an open-market purchase or sale.
According to prior grant terms, Goldman received 9,500 restricted stock units on August 13, 2024, vesting in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service.
Avalo Therapeutics, Inc. reported that two members of its board of directors, Dr. Jonathan Goldman and Mitchell Chan, have decided not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders. Both directors will continue serving on the board until that meeting.
The company stated that their decisions are not the result of any disagreement with Avalo on matters related to operations, policies, or practices. The board expressed its appreciation to Dr. Goldman and Mr. Chan for their service and contributions.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on IL-1β‑based treatments for immune‑mediated inflammatory diseases. Its lead antibody, abdakibart (AVTX‑009), is in a Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.
The company is prioritizing completion of this trial and planning potential Phase 3 studies and indication expansion while exploring strategic alternatives for several legacy programs. As of December 31, 2025, Avalo reported $98.3 million in cash, cash equivalents and short‑term investments and $12.9 million in current liabilities, and believes existing funds can support operations into 2028, though additional capital will likely be needed before Phase 3 or broader development.
Avalo Therapeutics reported 2025 results and highlighted progress on its lead drug abdakibart (AVTX-009). The company expects topline data from its Phase 2 LOTUS trial in hidradenitis suppurativa in the second quarter of 2026, a key milestone for its IL‑1β-based strategy.
Cash, cash equivalents and short-term investments were $98.3 million as of December 31, 2025, which Avalo expects will fund operations into 2028. Research and development expenses rose to $50.1 million and general and administrative expenses to $22.9 million, contributing to a net loss of $78.3 million for 2025.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold shares in a linked set of transactions. On March 16, 2026, she exercised options to acquire 19,500 shares of common stock at $12.65 per share and 5,992 shares at $8.04 per share.
The same day, she sold 25,492 shares of common stock in open-market transactions at an average price of about $16.1465 per share, in multiple trades between $16.00 and $16.34. Following these transactions, she directly holds 3,622 common shares.
FMR LLC reports beneficial ownership of 2,125,819 shares (11.5%) of Avalo Therapeutics Inc common stock as of 02/27/2026. The filing states FMR LLC has sole voting and dispositive power over those shares and names Abigail P. Johnson with sole dispositive power; signatures reference powers of attorney and an Exhibit 99 13d-1(k)(1) agreement.
Avalo Therapeutics, Inc. reported that Chief Legal Officer Paul Varki received a grant of stock options covering 80,000 shares on February 26, 2026. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the vesting terms, 25% of the option grant will vest on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting is conditioned on Varki's continued service with the company on each applicable vesting date.
Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley received a grant of stock options giving her the right to buy 95,000 shares of common stock. The award was reported at a price of $0.00 per share, reflecting a compensatory option grant rather than an open-market trade.
According to the disclosure, the option vests 25% on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years, as long as she continues in service on each vesting date. This filing shows an increase in her derivative equity holdings through a grant/award acquisition, not a sale of existing shares.
Avalo Therapeutics, Inc. disclosed that Chief Medical Officer Mittie Doyle received a grant of stock options for 105,000 shares on February 26, 2026. The option has an exercise price reported as $0.0000 per share. Twenty‑five percent vests on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, conditioned on continued service.